Unknown

Dataset Information

0

Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease.


ABSTRACT: Increasing evidence supports a role for abnormal immune activation and inflammatory responses in Huntington disease (HD). In this study, we evaluated the therapeutic potential of laquinimod (1 and 10?mg/kg), a novel immunomodulatory agent shown to be protective in a number of neuroinflammatory conditions, in the YAC128 mouse model of HD. Treatment with laquinimod for 6 months rescued atrophy in the striatum, in certain cortical regions, and in the corpus callosum of YAC128 HD mice. Diffusion tensor imaging showed that white matter microstructural abnormalities in the posterior corpus callosum were improved following treatment with low dose (1?mg/kg) laquinimod, and were paralleled by reduced levels of interleukin-6 in the periphery of YAC128 HD mice. Functionally, treatment with laquinimod (1 and 10?mg/kg) led to modest improvements in motor function and in depressive-like behaviour. Taken together, these results suggest that laquinimod may improve some features of pathology in HD, and provides support for the role of immune activation in the pathogenesis of HD.

SUBMITTER: Garcia-Miralles M 

PROVIDER: S-EPMC4985819 | biostudies-other | 2016

REPOSITORIES: biostudies-other

altmetric image

Publications

Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease.

Garcia-Miralles Marta M   Hong Xin X   Tan Liang Juin LJ   Caron Nicholas S NS   Huang Yihui Y   To Xuan Vinh XV   Lin Rachel Yanping RY   Franciosi Sonia S   Papapetropoulos Spyros S   Hayardeny Liat L   Hayden Michael R MR   Chuang Kai-Hsiang KH   Pouladi Mahmoud A MA  

Scientific reports 20160816


Increasing evidence supports a role for abnormal immune activation and inflammatory responses in Huntington disease (HD). In this study, we evaluated the therapeutic potential of laquinimod (1 and 10 mg/kg), a novel immunomodulatory agent shown to be protective in a number of neuroinflammatory conditions, in the YAC128 mouse model of HD. Treatment with laquinimod for 6 months rescued atrophy in the striatum, in certain cortical regions, and in the corpus callosum of YAC128 HD mice. Diffusion ten  ...[more]

Similar Datasets

2023-01-02 | PXD030831 | Pride
| S-EPMC2892238 | biostudies-literature
| S-EPMC9246276 | biostudies-literature
| S-EPMC7559237 | biostudies-literature
| S-EPMC3468776 | biostudies-literature
| S-EPMC5841207 | biostudies-literature
| S-EPMC4583330 | biostudies-literature
| S-EPMC4827723 | biostudies-literature
| S-EPMC8222368 | biostudies-literature
| S-EPMC6291617 | biostudies-literature